Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition.
Research evidence suggests a dose-response relationship for the association between cannabis use and risk of psychosis. Such relationship seems to reflect an increased risk of psychosis not only as a function of frequent cannabis use, but also of high-potency cannabis use in terms of concentration of Δ-9-tetrahydrocannabinol (Δ9-THC), its main psychoactive component. This finding would be in line with the evidence that Δ9-THC administration induces transient psychosis-like symptoms in otherwise healthy individuals. Conversely, low-potency varieties would be less harmful because of their lower amount of Δ9-THC and potential compresence of another cannabinoid, cannabidiol (CBD), which seems to mitigate Δ9-THC detrimental effects. A growing body of studies begins to suggest that CBD may have not only protective effects against the psychotomimetic effects of Δ9-THC but even therapeutic properties on its own, opening new prospects for the treatment of psychosis. Despite being more limited, evidence of the effects of cannabis on cognition seems to come to similar conclusions, with increasing Δ9-THC exposure being responsible for the cognitive impairments attributed to recreational cannabis use while CBD preventing such effects and, when administered alone, enhancing cognition. Molecular evidence indicates that Δ9-THC and CBD may interact with cannabinoid receptors with almost opposite mechanisms, with Δ9-THC being a partial agonist and CBD an inverse agonist/antagonist. With the help of imaging techniques, pharmacological studies in vivo have been able to show opposite effects of Δ9-THC and CBD also on brain function. Altogether, they may account for the intoxicating and therapeutic effects of cannabis on psychosis and cognition.
Keywords: cannabidiol; cognition; endocannabinoid system; psychosis; Δ-9-tetrahydrocannabinol.
Copyright © 2020 Colizzi, Ruggeri and Bhattacharyya.
Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition.
Curr Addict Rep. 2017;4(2):62-74. doi: 10.1007/s40429-017-0142-2. Epub 2017 Apr 29. Curr Addict Rep. 2017. PMID: 28580227 Free PMC article. Review.
A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35. doi: 10.1007/s00406-019-00978-2. Epub 2019 Jan 19. Eur Arch Psychiatry Clin Neurosci. 2019. PMID: 30661105 Clinical Trial.
Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Psychopharmacology (Berl). 2019 Sep;236(9):2713-2724. doi: 10.1007/s00213-019-05246-8. Epub 2019 May 1. Psychopharmacology (Berl). 2019. PMID: 31044290 Free PMC article. Clinical Trial.
Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Eur Neuropsychopharmacol. 2015 Mar;25(3):325-34. doi: 10.1016/j.euroneuro.2014.11.014. Epub 2014 Dec 5. Eur Neuropsychopharmacol. 2015. PMID: 25534187 Free PMC article. Clinical Trial.
A systematic review of the antipsychotic properties of cannabidiol in humans.
Schizophr Res. 2015 Mar;162(1-3):153-61. doi: 10.1016/j.schres.2015.01.033. Epub 2015 Feb 7. Schizophr Res. 2015. PMID: 25667194 Review.
- Appiah-Kusi E., Petros N., Wilson R., Colizzi M., Bossong M. G., Valmaggia L., et al. (2020). Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology 237 1121–1130. 10.1007/s00213-019-05442-6 – DOI – PMC – PubMed
L’article Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition. est apparu en premier sur Cannabis Belgique.